Dr. Long on Dabrafenib/Trametinib in BRAF V600E-Mutant Melanoma

Source: OncLive, August 2019


Georgina V. Long, BSc, PhD, MBBS, FRACP, co-medical director of Melanoma Institute Australia (MIA), chair of Melanoma Medical Oncology and Translational Research at MIA and Royal North Shore Hospital, University of Sydney, discusses results from the 5-year analysis of the combination of dabrafenib and trametinib in patients with BRAF V600E-mutant melanoma.

Long presented the 5-year pooled data of the phase III COMBI-v and COMBI-d trials at the 2019 ASCO Annual Meeting. In both trials, investigators tested the combination versus a BRAF inhibitor alone. The COMBI-d trial looked at the combination compared with dabrafenib alone, while the COMBI-v trial looked at the combination compared with vemurafenib alone, says Long. The analysis encapsulated over 500 patients who received the combination. Data showed a 5-year overall survival (OS) rate of 34%. In certain populations, the 5-year OS rate exceeded 50%, adds Long.

read the original full article